{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-001254","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.370541+00:00","generated_at":"2026-05-16T10:51:30.917522+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lipocine: Phase 3 PPD trial passes second DSMB safety review; topline data due Q2 2026","bullets":["DSMB reviewed safety data from 82 randomized patients; recommended trial continue without modification.","No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported.","Study no longer screening new participants; still enrolling eligible patients.","Topline safety and efficacy results expected early Q2 2026; data to support NDA submission.","CEO cites confidence in safety profile; potential for new treatment paradigm."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-001254","json":"https://secwatch.observer/filing/0001493152-26-001254.json","markdown":"https://secwatch.observer/filing/0001493152-26-001254.md","text":"https://secwatch.observer/filing/0001493152-26-001254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/0001493152-26-001254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:51:30.917522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}